We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Controversies in Internal Medicine |

Rebuttal by Drs Oottamasathien and Crawford

Siam Oottamasathien, MD; E. David Crawford, MD
Arch Intern Med. 2003;163(6):665-666. doi:10.1001/archinte.163.6.665.
Text Size: A A A
Published online


THERE IS certainly a heated controversy surrounding prostate cancer screening with PSA and DRE. Dr Hoffman makes a fair argument against screening, but the key issue is that we as physicians need to routinely discuss and educate our patients to the risks and benefits of screening. Once again, knowledge is power.

Dr Hoffman is correct that there is no good method to prevent prostate cancer, but it is not entirely true that men with advanced cancers can be treated only from a palliative standpoint. Traditionally, hormone therapy has been used in prostate cancer with locally advanced disease and/or metastatic disease. Currently, several trials indicate a survival advantage with the use of early hormonal intervention for prostate cancer. For example, the Medical Research Council study1 randomized patients with nonmetastatic locally advanced disease (stage T3) to 1 of 2 study arms: #11) early, lifelong hormonal therapy in conjunction with either orchiectomy or therapy with a luteinizing hormone–releasing hormone agonist, or #12) delayed therapy begun at the appearance of symptoms. Early hormonal intervention was associated with a decreased incidence of comorbid events and a significant survival advantage. In another study, conducted by the Eastern Cooperative Oncology Group (ECOG),2 patients who had undergone radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases (D1) were randomly assigned to either immediate treatment with antiandrogen therapy or to observation until disease progression was noted. The median duration of follow-up was 7.1 years (range, 3-10 years). Patients receiving immediate antiandrogen therapy demonstrated improved survival, reduced risk of recurrence, and decreased morbidity compared with the patients who were merely observed.2 These studies illustrate that men with advanced cancers can be treated in a palliative fashion and have a significant survival advantage.

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles